It has been almost seven months since the World Health Organisation (WHO) declared a public health emergency of international concern, or PHEIC; the most severe indicator that the health of the international community at large is at risk. The declaration of course related to the emergence of SARS-CoV-2, otherwise known as COVID-19. Though data is made murky by a lack of standardized testing and reporting, the WHO approximates over 24.3 million confirmed cases worldwide and attributes over 800,000 deaths to the SARS-CoV-2 virus.

SARS-CoV-2: The Struggle for Rapid Diagnostics

Thus far, regional and international efforts have been placed squarely upon containing the virus to limit its spread. This is what the media largely refers to in short-hand as flattening the curve. Yet this is essentially a holding method. The behind-the-scenes struggle to create appropriate prophylactic interventions using structural proteins is at the forefront of the ongoing battle against SARS-CoV-2; just as it was with other respiratory diseases like SARS-CoV and MERS.

Through diligent research and development (R&D), the ACROBiosystems team has engineered a range of SARS-CoV-2 antigen proteins for COVID-19 diagnostics. The problem with many established testing methodologies, such as reverse transcription-polymerase chain reactions (RT-PCR) which use an RNA template to detect SARS-CoV-2 genes, is that they are relatively slow and inconvenient. By contrast, antibody and antigen detection of COVID-19 infection are rapid, enabling faster diagnostics with some kits approaching instant detection.

SARS-CoV-2 Antigen Proteins

The ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a suite of high-quality recombinant proteins as well as spike glycoprotein and nucleocapsid protein antigens. Each of these SARS-CoV-2 antigen proteins is derived from either HEK293 cell lines or E. coli and is recommended for a variety of antibody detection methods such as chemiluminescent immunoassay, enzyme-linked immunosorbent assay (ELISA), gold immunochromatography, and so on. These serological systems are intended to accelerate SARS-CoV-2 screening techniques, with fully validated bioactivity and outstanding batch-to-batch consistency.

We are now in the position to be able to offer free samples to researchers looking to develop advanced diagnostic kits for COVID-19. If you would like free samples of our SARS-CoV-2 antigen proteins for your diagnostic research, simply fill in this form today. Or, contact us today to speak with a member of the ACROBiosystems team directly.